<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680416</article-id><article-id pub-id-type="doi">10.3390/vaccines12121381</article-id><article-id pub-id-type="publisher-id">vaccines-12-01381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Post-Pandemic Perspectives: Willingness, Risk Perception and Factors Influencing COVID-19 Booster Vaccine Uptake Among Thai Healthcare Workers and Vulnerable Populations</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4435-8090</contrib-id><name><surname>Kitro</surname><given-names>Amornphat</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01381" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9183-4582</contrib-id><name><surname>Sirikul</surname><given-names>Wachiranun</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01381" ref-type="aff">2</xref><xref rid="af3-vaccines-12-01381" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Polpitakchai</surname><given-names>Chanachai</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0479-4923</contrib-id><name><surname>Panumasvivat</surname><given-names>Jinjuta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01381" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yamsiri</surname><given-names>Ranchana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Tasena</surname><given-names>Pacharee</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af4-vaccines-12-01381" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Punyaphab</surname><given-names>Chutima</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af4-vaccines-12-01381" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6691-5428</contrib-id><name><surname>Rungsiyakull</surname><given-names>Chaiy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af5-vaccines-12-01381" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0379-2798</contrib-id><name><surname>Sapbamrer</surname><given-names>Ratana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01381" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4781-4119</contrib-id><name><surname>Siviroj</surname><given-names>Penprapa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1683-4259</contrib-id><name><surname>Srithanaviboonchai</surname><given-names>Kriengkrai</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-12-01381" ref-type="aff">1</xref><xref rid="af6-vaccines-12-01381" ref-type="aff">6</xref><xref rid="c1-vaccines-12-01381" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Marchesi</surname><given-names>Federico</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Ricc&#x000f2;</surname><given-names>Matteo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01381"><label>1</label>Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; <email>amornphat.kit@cmu.ac.th</email> (A.K.); </aff><aff id="af2-vaccines-12-01381"><label>2</label>Environmental and Occupational Medicine Excellence Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand</aff><aff id="af3-vaccines-12-01381"><label>3</label>Center of Data Analytics and Knowledge Synthesis for Health Care, Chiang Mai University, Chiang Mai 50200, Thailand</aff><aff id="af4-vaccines-12-01381"><label>4</label>Health Promotion Unit, Maharaj Nakorn Chiang Mai, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand</aff><aff id="af5-vaccines-12-01381"><label>5</label>Department of Mechanical Engineering, Faculty of Engineering, Chiang Mai University, Chiang Mai 50200, Thailand</aff><aff id="af6-vaccines-12-01381"><label>6</label>Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand</aff><author-notes><corresp id="c1-vaccines-12-01381"><label>*</label>Correspondence: <email>kriengkrai.s@cmu.ac.th</email>; Tel.: +66-818856142</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1381</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>30</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: The emergence of new COVID-19 variants continues to affect healthcare workers (HCWs) and vulnerable populations in the post-pandemic era. This study aims to assess the willingness, perceptions, and factors associated with booster COVID-19 vaccine uptake in this context. Methods: A cross-sectional study was conducted between October 2023 and May 2024 among Thai adults (&#x0003e;20 years old) in Chiang Mai, Northern Thailand. Participants included HCWs and patients with chronic medical conditions. People who had received a monovalent XBB-derived booster vaccine were excluded. Results: Data related to a total of 811 participants were analyzed, with 328 from the vulnerable group and 483 HCWs. Willingness to receive the booster was similar in both groups (43.3% in HCWs, 45.0% in the vulnerable group). Low-risk perception (59.6%&#x02013;83.5%), minimal impact on daily life (60.4%&#x02013;62.9%), and doubts about booster efficacy (75.9%&#x02013;81.4%) were prevalent negative thoughts toward the booster. Having received a flu vaccine (aOR 2.1), concerns about the impact on life of COVID-19 (aOR 1.8), and beliefs in booster safety (aOR 1.8) and vaccine effectiveness against severe disease (aOR 2.7) were associated with increased willingness. Conclusions: Only 44% of participants were willing to receive a COVID-19 booster. Policymakers can use these insights to develop strategies to increase vaccine uptake in the post-pandemic era.</p></abstract><kwd-group><kwd>COVID-19 vaccine post-pandemic</kwd><kwd>risk perception</kwd><kwd>Thailand</kwd><kwd>healthcare workers</kwd><kwd>high-risk groups</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01381"><title>1. Introduction</title><p>COVID-19 emerged as a global pandemic and a critical international public health emergency between 2020 and 2023, profoundly impacting individual health, communities, and the social and economic climate worldwide [<xref rid="B1-vaccines-12-01381" ref-type="bibr">1</xref>]. According to the latest World Health Organization (WHO) epidemiological update in October 2024, the cumulative global case count reached 776 million, with more than 7 million deaths [<xref rid="B2-vaccines-12-01381" ref-type="bibr">2</xref>]. However, this number may underestimate the true number due to reduced testing, sequencing, and reporting capacities. Surveillance of viral load in wastewater suggests the actual burden could be clinically underestimated by between two and nineteen times [<xref rid="B3-vaccines-12-01381" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01381" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01381" ref-type="bibr">5</xref>]. Until recently, there was still a seasonal surge causing morbidity and mortality from new variants, immune waning from vaccination or infection, and reduced adherence to personal protective measures [<xref rid="B6-vaccines-12-01381" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01381" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01381" ref-type="bibr">8</xref>]. Omicron variants are currently spreading with many mutations, including variants of interest (VOIs) BA.2.86 and JN.1 and variants under monitoring (VUMs)&#x02014;JN.1.7, JN.1.18, KP.2, KP.3, KP.3.1.1, LB.1, and XEC. All variants spread easily [<xref rid="B2-vaccines-12-01381" ref-type="bibr">2</xref>].</p><p>COVID-19 vaccines currently available are typically around 60% effective in preventing the disease and can reduce hospitalizations, deaths, and instances of long COVID-19 by about 80% [<xref rid="B9-vaccines-12-01381" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01381" ref-type="bibr">10</xref>]. However, the effectiveness of vaccines tends to decrease over time, usually within 3&#x02013;6 months after vaccination. Especially among older individuals with chronic illnesses, vaccine effectiveness drops from 87% one month after vaccination to 47% after five months [<xref rid="B11-vaccines-12-01381" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01381" ref-type="bibr">12</xref>]. Healthcare workers (HCWs) and people with underlying chronic conditions are at higher risk and should receive at least three vaccine doses and regular booster shots to protect against future COVID-19 variants [<xref rid="B13-vaccines-12-01381" ref-type="bibr">13</xref>]. A study conducted in Qatar and Israel showed that receiving a third booster dose significantly reduced illness by around 50% and lowered mortality and severe complications by more than 70% compared to those who received only two vaccine doses [<xref rid="B14-vaccines-12-01381" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01381" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-01381" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01381" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01381" ref-type="bibr">18</xref>]. This strategy has been adopted as policy in many countries based on WHO recommendations, which include transitioning from a bivalent to a monovalent XBB-derived COVID-19 vaccine [<xref rid="B11-vaccines-12-01381" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01381" ref-type="bibr">12</xref>,<xref rid="B19-vaccines-12-01381" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01381" ref-type="bibr">20</xref>]. </p><p>A meta-analysis revealed that the willingness rate of uptake of COVID-19 booster vaccines is high, reaching 81%. However, healthcare workers show a lower willingness rate at 66% compared to the general population, and willingness is notably lowest among Southeast Asians, with only 52%, a rate similar to the level of acceptance observed during the early COVID-19 vaccine rollout in Thailand [<xref rid="B21-vaccines-12-01381" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-01381" ref-type="bibr">22</xref>]. Factors influencing acceptance of booster vaccines include increasing age, having chronic diseases such as cancer, trust in vaccine efficacy, history of receiving seasonal influenza vaccine, positive attitude towards vaccination, confidence in vaccine safety, recommendation by healthcare personnel, access to adequate vaccine information, belief that healthcare personnel are at high risk of COVID-19 infection, belief in the severity of COVID-19, being a healthcare professional, and not having contracted COVID-19 previously [<xref rid="B23-vaccines-12-01381" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01381" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01381" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01381" ref-type="bibr">26</xref>]. On the contrary, factors contributing to vaccine refusal include experiencing severe adverse reactions after prior vaccination and lack of belief in vaccine efficacy [<xref rid="B23-vaccines-12-01381" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01381" ref-type="bibr">24</xref>], especially among individuals who experienced breakthrough infections after vaccination, which doubled the propensity for vaccine refusal [<xref rid="B21-vaccines-12-01381" ref-type="bibr">21</xref>,<xref rid="B27-vaccines-12-01381" ref-type="bibr">27</xref>]. Vaccine hesitancy (VH) remains a significant challenge. About 44% of American healthcare workers who had not yet received a booster dose were concerned about potential side effects, citing the rapid development of the vaccines as a key reason for their hesitation (27%) and low perceived risk of infection (27%) [<xref rid="B28-vaccines-12-01381" ref-type="bibr">28</xref>]. While patient concerns were related to the necessity for a vaccine (64%), safety (60%) and vaccine effectiveness (54%) [<xref rid="B28-vaccines-12-01381" ref-type="bibr">28</xref>].</p><p>Currently, many countries have implemented policies for administering a booster dose now that COVID-19 has become an endemic disease, with most recommending the monovalent COVID-19 XBB-derived vaccine [<xref rid="B29-vaccines-12-01381" ref-type="bibr">29</xref>]. Information on vaccine willingness among healthcare professionals and vulnerable individuals remains essential due to the ongoing outbreaks of the Omicron variants and the potential emergence of new variants. This study aims to explore willingness, perceptions, and associated factors regarding COVID-19 booster doses among Thai healthcare workers and high-risk individuals during the post-pandemic era. Understanding the demand for booster doses and the factors influencing the willingness to accept a vaccine is crucial for policymakers to inform targeted strategies and health promotion activities aimed at high-risk groups. These efforts could improve vaccination uptake, enhance the protection of these key populations, and support broader public health goals.</p></sec><sec id="sec2-vaccines-12-01381"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-12-01381"><title>2.1. Setting and Study Design</title><p>This cross-sectional study took place in Chiang Mai, Northern Thailand, between October 2023 and May 2024. Participants included HCWs at Maharaj Nakorn Chiang Mai, which is a medical school and tertiary care facility, and patients seeking treatment for chronic medical conditions (<xref rid="vaccines-12-01381-f001" ref-type="fig">Figure 1</xref>). In this study, the vulnerable population was defined as adults with medical conditions including obesity, diabetes, lipid profile, cardiovascular, chronic lung disease, asthma, chronic kidney disease, and immunocompromised status who are at a higher risk of severe illness from COVID-19. HCWs were recruited for the study when they visited the health promotion unit for vaccinations or health check-ups. Vulnerable populations were invited to participate during their outpatient visits to the Internal Medicine Department or during health check-ups at Maharaj Nakorn Chiang Mai Hospital. A trained research team assisted participants and asked for their consent to join the study and complete the questionnaire. The study included Thai adults aged 20 and above, encompassing HCWs, elderly individuals, and adults with chronic pulmonary diseases, cardiovascular diseases, chronic kidney disease, obesity, cancer, and diabetes mellitus. Potential participants who had received a monovalent XBB-derived booster vaccine were excluded. The study utilized a questionnaire divided into three sections: sociodemographic information, attitudes towards COVID-19 disease and COVID-19 booster vaccines, and factors influencing willingness to accept COVID-19 vaccine boosters. The questionnaire was developed based on prior research [<xref rid="B22-vaccines-12-01381" ref-type="bibr">22</xref>] and underwent face validity testing through a pilot study involving 50 individuals, which confirmed its reliability and validity as assessed by experts. Sample size calculations were based on an estimated willingness to vaccinate among those with chronic medical conditions (P<sub>1</sub> = 0.66) and healthcare workers (P<sub>2</sub> = 0.52) [<xref rid="B21-vaccines-12-01381" ref-type="bibr">21</xref>], with an alpha error of 0.05 and a beta error of 0.05. The calculated sample size was determined to be 775 individuals per group, and accounting for a 5% dropout rate, a total of 813 participants were needed for both groups.</p></sec><sec id="sec2dot2-vaccines-12-01381"><title>2.2. Questionnaire</title><p>The research gathered demographic information from participants, encompassing details such as age, gender, occupation, education level, presence of chronic medical conditions, symptoms experienced during the most recent COVID-19 infection, categorized as mild (no medication needed), moderate (requiring medication), or severe (requiring hospitalization), history of COVID-19 among friends or family member, history of self-reported long COVID-19 (symptoms persisting for at least 3 months after SARS-CoV-2 infection), history of COVID-19 diagnosis, history of COVID-19 vaccination including the number of previous COVID-19 vaccinations, uptake of the bivalent COVID-19 vaccine, and history of flu vaccination during the last season. Additionally, participants&#x02019; perceptions towards COVID-19 were assessed, including perceived risk of future infection, perception of disease severity, the impact of COVID-19 on daily life and work, and willingness to receive a booster vaccine. This assessment also explored concerns related to vaccine side effects, safety, and efficacy. Perception was assessed using a five-level Likert scale, ranging from the lowest degree (1) to the highest degree (5). Responses of &#x0201c;Strongly agree&#x0201d; and &#x0201c;Agree&#x0201d; were considered as indicating a high perceived risk, while &#x0201c;Neither agree nor disagree&#x0201d;, &#x0201c;Disagree&#x0201d;, and &#x0201c;Strongly disagree&#x0201d; were categorized as reflecting a low perceived risk. The questionnaire was adapted from a previous study on vaccine acceptance and attitudes among the Thai population, with a validity score greater than 0.5 [<xref rid="B22-vaccines-12-01381" ref-type="bibr">22</xref>]. Of 811 overall participants, the attitude assessment demonstrated an excellent internal consistency in both Cronbach&#x02019;s &#x003b1; (0.82; 95% CI 0.80&#x02013;0.85). We also performed a subgroup analysis of vulnerable and healthcare worker groups to ensure the reliability of the assessment, which were 0.83 (95% CI 0.79&#x02013;0.87) and 0.82 (95% CI 0.79&#x02013;0.85), respectively.</p></sec><sec id="sec2dot3-vaccines-12-01381"><title>2.3. Statistical Analysis</title><p>All statistical analyses were conducted using the STATA statistical software program (Stata Corp. 2023, Stata Statistical Software: Release 18, Stata Corp LLC, College Station, TX, USA). Descriptive statistics, including percentage, mean, and standard deviation (SD), were used to evaluate quantitative data from the questionnaire. Independent student T-tests and chi-square tests were used to analyze the differences in demographic data between the two groups. A multivariable logistic regression was analyzed to determine the independent determinants associated with COVID-19 vaccine willingness. Adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) were presented as outcome parameters, which represented the magnitude of association between potential determinants with COVID-19 vaccine willingness. The statistical significance was set at a two-sided <italic toggle="yes">p</italic>-value below 0.05. The potential determinants, which were considered to explore in a multivariable logistic regression, were body mass index, participant groups (vulnerable and healthcare workers groups), chronic medical conditions, history of COVID-19 infection and vaccination, and attitude toward COVID-19 disease and COVID-19 vaccination. Other sociodemographic variables, including age, gender, education level, and marital status, were entered into the model as the potential confounders.</p></sec><sec id="sec2dot4-vaccines-12-01381"><title>2.4. Ethical Considerations </title><p>The informed consent, questionnaires, and study protocol received approval from the Research Ethics Committee of the Faculty of Medicine at Chiang Mai University (Ethical Approval Number: COM-2566-0404). Verbal informed consent was obtained from each participant before they joined the study, and participants were given the option to skip questions or withdraw their consent at any time.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01381"><title>3. Results</title><p>In this study, 811 participants were enrolled and divided into two groups: 328 in the vulnerable group and 483 HCWs (<xref rid="vaccines-12-01381-t001" ref-type="table">Table 1</xref>). Among the vulnerable group, the mean age was 52.7 years (SD = 16.5), with 61.3% (<italic toggle="yes">n</italic> = 201) being female, 15.2% (<italic toggle="yes">n</italic> = 50) had a body weight greater than 100 kg, 48.2% (<italic toggle="yes">n</italic> = 158) had a bachelor&#x02019;s degree or higher education, and 57.9% (<italic toggle="yes">n</italic> = 190) were married. Regarding health conditions, 65.2% (<italic toggle="yes">n</italic> = 214) had cardiovascular diseases, 49.1% (n = 161) had hypertension, 41.8% (<italic toggle="yes">n</italic> = 137) had diabetes mellitus (DM), 35.7% (<italic toggle="yes">n</italic> = 117) had high cholesterol levels, 6.1% (<italic toggle="yes">n</italic> = 20) had chronic kidney disease, and 8.5% (<italic toggle="yes">n</italic> = 28) had cerebrovascular disease. With regard to COVID-19, 46.6% (n = 153) had a history of COVID-19 infection, with 10.7% (<italic toggle="yes">n</italic> = 35) experiencing mild symptoms and 32.9% (<italic toggle="yes">n</italic> = 108) having moderate symptoms that required medication; 14% (n = 46) reported long COVID-19 symptoms, and 37.8&#x02013;50.3% (<italic toggle="yes">n</italic> = 124&#x02013;165) had friends or family members who contracted COVID-19. Among the participants, 74.1% (n = 243) had their last COVID-19 infection more than one year after vaccination. In terms of vaccination, 91.1% (<italic toggle="yes">n</italic> = 297) had received COVID-19 vaccinations, with an average of three shots (IQR 2&#x02013;4), with 10.4% (<italic toggle="yes">n</italic> = 34) receiving the bivalent COVID-19 vaccine. Side effects from the COVID-19 vaccine were reported by 26.2% (<italic toggle="yes">n</italic> = 86), with 25.3% (<italic toggle="yes">n</italic> = 83) experiencing mild symptoms such as pain at the injection site and low-grade fever. Additionally, 48% (<italic toggle="yes">n</italic> = 157) had received a flu shot within the past year, and only 17.7% (<italic toggle="yes">n</italic> = 58) had a history of vaccine refusal. Around 45% (<italic toggle="yes">n</italic> = 147) were willing to receive the monovalent XBB-derived vaccine if it became available.</p><p>Among the HCWs group, the mean age was 42.2 years (SD = 13.0), with 85.3% (<italic toggle="yes">n</italic> = 412) being female. 8.9% (<italic toggle="yes">n</italic> = 43) had a body weight greater than 100 kg, 72.9% (<italic toggle="yes">n</italic> = 352) had a bachelor&#x02019;s degree or higher education, 53.8% (<italic toggle="yes">n</italic> = 260) were single, and 39.1% (<italic toggle="yes">n</italic> = 189) were married. 32.9% (<italic toggle="yes">n</italic> = 267) were nurses, followed by medical assistants (21.0%, <italic toggle="yes">n</italic> = 170) and doctors (4.8%, <italic toggle="yes">n</italic> = 39). 17.3% (<italic toggle="yes">n</italic> = 140) provided direct care for COVID-19 patients, and 40.9% (<italic toggle="yes">n</italic> = 332) were involved in caring for COVID-19 patients. Regarding health conditions, 12.2% (<italic toggle="yes">n</italic> = 59) had hypertension, 3.9% (<italic toggle="yes">n</italic> = 19) had DM, 8.5% (<italic toggle="yes">n</italic> = 41) had high cholesterol levels, 1.2% (<italic toggle="yes">n</italic> = 6) had chronic kidney disease, and 2.7% (<italic toggle="yes">n</italic> = 13) had cerebrovascular disease. With regard to COVID, 68.5% (<italic toggle="yes">n</italic> = 331) had a history of COVID-19 infection, with 20.9% (<italic toggle="yes">n</italic> = 101) experiencing mild symptoms and 46.6% (<italic toggle="yes">n</italic> = 225) having moderate symptoms that required medication; 24.2% (<italic toggle="yes">n</italic> = 117) reported long COVID-19 symptoms and 72.7&#x02013;81.8% (<italic toggle="yes">n</italic> = 351&#x02013;395) had friends or family members who contracted COVID-19. Among the participants, 70.2% (<italic toggle="yes">n</italic> = 339) had their last COVID-19 infection more than one year after vaccination. In terms of vaccination, 98.6% (<italic toggle="yes">n</italic> = 476) had received COVID-19 vaccinations, with an average of four shots (IQR 3&#x02013;5); 32.1% (<italic toggle="yes">n</italic> = 155) had received the bivalent COVID-19 vaccine. Side effects from the COVID-19 vaccine were reported by 43.5% (<italic toggle="yes">n</italic> = 210), who experienced mild symptoms such as pain at the injection site and low-grade fever. Additionally, 75.4% (<italic toggle="yes">n</italic> = 364) had received a flu shot within the past year, and only 37.9% (<italic toggle="yes">n</italic> = 183) had a history of vaccine refusal. Around 43.3% (<italic toggle="yes">n</italic> = 209) were willing to receive the monovalent XBB-derived vaccine if it became available.</p><p>In <xref rid="vaccines-12-01381-t002" ref-type="table">Table 2</xref>, the attitudes toward COVID-19 and COVID-19 booster vaccine with monovalent XBB-derived are compared between the two groups. The results show that vulnerable individuals perceive a significantly lower risk of contracting COVID-19 in the future (83.5% vs. 59.6%, <italic toggle="yes">p</italic> &#x0003c; 0.001) but believe they have a significantly low risk of severe illness if infected (63.7% vs. 69.6%, <italic toggle="yes">p</italic> = 0.032). Both groups reported a similar low risk of COVID-19 impacting their daily lives (60.4.% vs. 62.9%, <italic toggle="yes">p</italic> = 0.380). When considering the impact of COVID-19 on work, vulnerable individuals felt more at a low-risk level compared to healthcare workers (59.8% vs. 51.6%, <italic toggle="yes">p</italic>-value = 0.030). Concerns about receiving a booster vaccine were similar between the groups (33.5% vs. 32.3%, <italic toggle="yes">p</italic> = 0.86), as were concerns about the side effects of booster vaccines (41.2% vs. 37.3%, <italic toggle="yes">p</italic> = 0.250). However, vulnerable individuals were significantly more likely to believe that booster vaccines are safe (29.3% vs. 20.7%, <italic toggle="yes">p</italic> = 0.009). Both groups had similar levels of belief that booster vaccines would prevent new strains of COVID-19 (23.8% vs. 18.6%, <italic toggle="yes">p</italic> = 0.095) and severe infection from new variants (32.9% vs. 29.8%, <italic toggle="yes">p</italic> = 0.300).</p><p>In <xref rid="vaccines-12-01381-t003" ref-type="table">Table 3</xref>, the factors influencing the willingness of vulnerable individuals and healthcare workers to accept a COVID-19 booster with the monovalent XBB-derived vaccine after the pandemic era are shown. Among the vulnerable group, 78.3% (<italic toggle="yes">n</italic> = 256) made the decision to acquire vaccination on their own, followed by 48.9% (<italic toggle="yes">n</italic> = 160) who were influenced by their friends and family members. In contrast, almost 90% (<italic toggle="yes">n</italic> = 431) of healthcare workers made the decision independently. Both groups had similar concerns about the monovalent XBB-derived booster vaccine (73.1% vs. 67.6%, <italic toggle="yes">p</italic> = 0.097), side effects (59.3% vs. 60.0%, <italic toggle="yes">p</italic> = 0.860), vaccine efficacy (36.4% vs. 39.6%, <italic toggle="yes">p</italic> = 0.350), and research on the vaccine (60.6% vs. 64.7%, <italic toggle="yes">p</italic> = 0.230). However, they differed significantly in terms of safety concerns (23.9% vs. 33.4%, <italic toggle="yes">p</italic> = 0.003). Regarding sources of information about the vaccine, the vulnerable group primarily relied on friends (53.5%, <italic toggle="yes">n</italic> = 175), the internet (38.8%, <italic toggle="yes">n</italic> = 127), and healthcare workers (33.9%, <italic toggle="yes">n</italic> = 111). </p><p>Seven factors were associated with the willingness to receive the COVID-19 monovalent XBB-derived vaccine. Individuals with a body weight greater than 100 kg were 2.46 times more willing (95% CI: 1.41&#x02013;4.31, <italic toggle="yes">p</italic> = 0.002). Each additional previous COVID-19 vaccination increased willingness by 1.15 times (95% CI: 1.03&#x02013;1.29, <italic toggle="yes">p</italic> = 0.014). A history of receiving a flu vaccine in the past year increased willingness by 2.07 times (95% CI: 1.40&#x02013;3.06, <italic toggle="yes">p</italic> &#x0003c; 0.001). Attitude towards COVID-19 impacting daily life increased willingness by 1.79 times (95% CI: 1.03&#x02013;3.14, <italic toggle="yes">p</italic> = 0.040), and attitude towards COVID-19 impacting work life increased willingness by 1.74 times (95% CI: 1.02&#x02013;2.95, <italic toggle="yes">p</italic> = 0.042). Belief in the safety of booster vaccines increased willingness by 1.85 times (95% CI: 1.11&#x02013;3.07, <italic toggle="yes">p</italic> = 0.017), and belief that boosters will prevent severe infection from new variants increased willingness by 2.65 times (95% CI: 1.57&#x02013;4.46, <italic toggle="yes">p</italic> &#x0003c; 0.001). Three factors were associated with hesitancy toward the COVID-19 monovalent XBB-derived vaccine. Healthcare workers were 42% less likely to be hesitant compared to the vulnerable group (aOR 0.58, 95% CI: 0.34&#x02013;0.98, <italic toggle="yes">p</italic> = 0.040). Individuals with a history of vaccine refusal were 44% less likely to be willing compared to those without a history of refusal (aOR 0.56, 95% CI: 0.37&#x02013;0.84, <italic toggle="yes">p</italic> = 0.005). Additionally, those concerned about receiving booster vaccines were 80% less likely to be willing compared to those who were not concerned (a OR 0.20, 95% CI: 0.11&#x02013;0.36, <italic toggle="yes">p</italic> &#x0003c; 0.001). (<xref rid="vaccines-12-01381-t004" ref-type="table">Table 4</xref>).</p></sec><sec sec-type="discussion" id="sec4-vaccines-12-01381"><title>4. Discussion</title><p>To the best of our knowledge, this was the first study conducted in Thailand to evaluate the willingness among healthcare workers and vulnerable patients post-pandemic to receive the monovalent XBB-derived COVID-19 booster vaccine. The willingness to receive the monovalent XBB-derived COVID-19 booster vaccine was 45.0% among vulnerable individuals and 43.3% among healthcare workers. Factors associated with a higher likelihood of getting the booster in the post-pandemic period included having a body weight over 100 kg, receiving a flu vaccine in the past year, perceiving that COVID-19 significantly affected daily life and work, believing in the safety of the booster, and trusting that the booster would prevent severe illness from new variants.</p><p>In our study, the willingness to receive a COVID-19 vaccine post-pandemic was around 44% among vulnerable groups and HCWs. This rate is notably lower than findings from a meta-analysis conducted during the pandemic up to June 2022, which reported an intention to receive a booster dose of 79% (95% CI 72&#x02013;85%) among the general population and 66% (95% CI 58&#x02013;74%) among HCWs [<xref rid="B21-vaccines-12-01381" ref-type="bibr">21</xref>]. Furthermore, our findings also show lower levels of willingness compared to studies conducted during the pandemic in 2021 among HCWs in Nepal, Vietnam, and Hong Kong, which reported willingness rates of 95.4%, 90.6%, and 54.4%, respectively [<xref rid="B30-vaccines-12-01381" ref-type="bibr">30</xref>]. In 2022, willingness to receive a booster dose among Chinese HCWs was reported at 76.4% [<xref rid="B24-vaccines-12-01381" ref-type="bibr">24</xref>]. Interestingly, our results are consistent with a study of the general population in Hong Kong during a period of low COVID-19 incidence (December 2021-January 2022), which found that only 42.2% intended to receive a booster dose [<xref rid="B31-vaccines-12-01381" ref-type="bibr">31</xref>]. This suggests a declining trend in the willingness to obtain a COVID-19 booster, and perhaps this study was conducted later or a longer time after the peak of the epidemic. Despite fluctuating willingness, actual uptake rates post-pandemic may be even lower. For example, a meta-analysis found that while the intention to receive a booster was around 79% among the general population, actual uptake was as low as 31% in some studies, particularly among those who expressed hesitancy or willingness [<xref rid="B21-vaccines-12-01381" ref-type="bibr">21</xref>,<xref rid="B23-vaccines-12-01381" ref-type="bibr">23</xref>,<xref rid="B32-vaccines-12-01381" ref-type="bibr">32</xref>]. These findings underscore the need for targeted efforts to emphasize the World Health Organization&#x02019;s recommendation that high-priority groups&#x02014;including adults with co-morbidities and healthcare workers in direct contact with patients&#x02014;should receive booster doses to maintain protection [<xref rid="B33-vaccines-12-01381" ref-type="bibr">33</xref>].</p><p>In our study, 83.5% of the vulnerable population and 59.6% of HCWs believed they were at low risk of contracting COVID-19 in the future. Additionally, 63.7% to 69.6% thought the disease would have low severity, 60.4% to 62.9% expected it to have minimal impact on their daily lives, and 51.6% to 59.8% anticipated little impact on their work life post-pandemic. These results are quite different compared to previous studies, systematic reviews, and research conducted in Thailand during the pandemic, which showed high-risk awareness, fear, and anxiety in the general population. During that time, society strictly adhered to preventive measures and daily life was greatly affected [<xref rid="B22-vaccines-12-01381" ref-type="bibr">22</xref>,<xref rid="B34-vaccines-12-01381" ref-type="bibr">34</xref>]. However, HCWs, especially those on the front lines and in direct contact with patients, may have had a higher sense of risk compared to the general population, largely due to a lack of adequate infection control measures, including protective gear and supportive facilities [<xref rid="B35-vaccines-12-01381" ref-type="bibr">35</xref>]. Our findings are also in alignment with a study from the U.S., where people&#x02019;s perception of risk decreased over time as they gained more experience regarding COVID-19 [<xref rid="B36-vaccines-12-01381" ref-type="bibr">36</xref>]. The slow rollout of vaccines, along with reduced media coverage and fewer public health messages, may also have contributed to this lower sense of risk [<xref rid="B36-vaccines-12-01381" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-01381" ref-type="bibr">37</xref>]. Although people&#x02019;s perception of risk can change over time, the risk of getting COVID-19 is never zero. It is important to continue reminding the public, especially vulnerable groups and HCWs, to take preventive actions to protect themselves from the disease.</p><p>In our study, 66.5&#x02013;67.7% of participants expressed low levels of concern about receiving a booster vaccine post-pandemic, though 37.3&#x02013;41.2% were highly concerned about potential side effects. Interestingly, 70.4&#x02013;79.3% believed the booster vaccine was safe. However, almost 81.4% of HCWs and the vulnerable population doubted the booster&#x02019;s effectiveness in preventing infection or severe illness from new COVID-19 variants. Social media and online platforms play a significant role in spreading both accurate information and misinformation. This is particularly true for anti-vaccine content, which often mimics the appearance of news or scientific reports, contributing to vaccine hesitancy. To effectively assess information, it is crucial to adopt various strategies, including fact-checking, evaluating the credibility of sources, and enhancing policies aimed at preventing the spread of misinformation [<xref rid="B38-vaccines-12-01381" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-12-01381" ref-type="bibr">39</xref>]. This is similar to findings from a study among U.S. HCWs, where 63.6% were concerned about the vaccine being ineffective against new strains [<xref rid="B40-vaccines-12-01381" ref-type="bibr">40</xref>]. In a similar study of HCWs in Italy, 54.6% of those who planned not to acquire a booster believed it offered no protection against emerging variants, and 27% were concerned about side effects [<xref rid="B25-vaccines-12-01381" ref-type="bibr">25</xref>]. These attitudes could be related to breakthrough infections and waning immunity in fully vaccinated individuals [<xref rid="B41-vaccines-12-01381" ref-type="bibr">41</xref>]. The effectiveness of the XBB-derived vaccine against infection was 52.2% (95% CI: 44.6&#x02013;58.7%) after 4 weeks, dropping to 20.4% (95% CI: 6.2&#x02013;32.5%) after 20 weeks. Its effectiveness against hospitalization was 57.1% (95% CI: 40.4&#x02013;69.2%) after 10 weeks for Omicron subvariants [<xref rid="B42-vaccines-12-01381" ref-type="bibr">42</xref>]. To successfully promote vaccination programs, enhancing perceptions of benefits alone may not be enough; the emphasis on vaccine safety, however, could be crucial in reducing vaccine hesitancy [<xref rid="B43-vaccines-12-01381" ref-type="bibr">43</xref>]. Some potential strategies include increasing health literacy campaigns to help vaccine recipients understand the importance of vaccination. Strengthening community engagement through social initiatives and improving healthcare workers&#x02019; communication and education skills are also key [<xref rid="B44-vaccines-12-01381" ref-type="bibr">44</xref>]. Additionally, the promotion of altruistic reasons and the highlighting of non-health benefits&#x02014;like the ability to travel safely&#x02014;could further encourage vaccine uptake [<xref rid="B45-vaccines-12-01381" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-12-01381" ref-type="bibr">46</xref>]</p><p>Our study found that factors such as receiving additional COVID-19 vaccines (1.2 times more likely), having a flu shot in the past year (2.1 times more likely), concerns about the impact of COVID-19 on daily and work life (1.8 times more likely), and beliefs about the safety (1.8 times more likely) and effectiveness against severe disease (2.7 times more likely) significantly increased the willingness to obtain booster vaccination in the post-pandemic era. These findings are in alignment with previous research from both Asian and Western countries, as well as systematic reviews, which also highlight the connection between receiving the flu vaccine in the previous season, confidence in vaccine safety, and COVID-19 booster uptake [<xref rid="B31-vaccines-12-01381" ref-type="bibr">31</xref>,<xref rid="B47-vaccines-12-01381" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-12-01381" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-01381" ref-type="bibr">49</xref>]. This suggests that future annual COVID-19 vaccine booster campaigns targeting healthcare workers (HCWs) and vulnerable populations could benefit from emphasizing the safety and effectiveness of vaccines in preventing severe disease, as well as how COVID-19 can affect everyday life and work life. These campaigns could initially focus on those who have already received the flu vaccine or prior COVID-19 vaccinations, using them as trusted sources of information. Coupled with healthcare provider guidance, this approach could help increase vaccine uptake, combat misinformation, and reduce vaccine hesitancy in the post-pandemic era.</p><p>Numerous international studies have reported lower vaccine uptake during or shortly after the peak of the outbreaks. What sets this study apart is its focus on high-risk populations, particularly individuals with chronic medical conditions-a group that has been underrepresented in prior research. Additionally, this is the first study to gather data from various groups of healthcare workers and vulnerable individuals with underlying medical conditions in tertiary care settings. Uniquely, it was conducted after COVID-19 transitioned to an endemic phase and targeted the monovalent XBB-derived vaccine rather than other monovalent or bivalent COVID-19 vaccines. The findings could help inform practical strategies for the annual administration of COVID-19 vaccines, ensuring continued protection for high-risk populations in the post-pandemic era. This study has several limitations. The cross-sectional design does not permit the establishment of causal relationships between the identified determinants and the willingness to receive a COVID-19 booster in the post-pandemic era. Additionally, the study used convenience sampling at a single center, with most participants being doctors, nurses, and patients in tertiary care settings. This limits the generalizability of the findings to other populations or settings. The distribution of the questionnaire might also have attracted participants with pre-existing biases, either pro-vaccine or anti-vaccine, which could have influenced the results. Conducting the study during the endemic phase also limits its ability to compare vaccine uptake patterns across different phases of the pandemic. Future research should adopt a better sampling strategy and aim to include a more diverse sample, including other allied healthcare workers and individuals with co-morbidities. Expanding the study to multiple centers or conducting it at the national level would provide a more comprehensive understanding of vaccine willingness among Thai citizens. This could help in the design of more effective vaccine rollout campaigns for healthcare workers and vulnerable populations, ensuring better protection against COVID-19.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01381"><title>5. Conclusions</title><p>COVID-19 vaccine willingness is relatively low (44%) among HCWs and vulnerable populations in the post-pandemic era. This reduction likely stems from reduced perceived risk, disease severity, impacts on daily and work life, and confidence in the boosters&#x02019; effectiveness. Those who trust the boosters&#x02019; safety and effectiveness received a flu vaccine, never refused vaccination, and recognized that COVID-19&#x02019;s impact may drive vaccine booster uptake. These individuals could serve as key advocates to encourage their peers, reduce vaccine hesitancy, and combat misinformation, helping to protect both themselves and their communities in the post-pandemic era. Policymakers could implement more effective strategies and health promotion activities targeted at high-risk groups.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all participants to participate in the study. We would like to express our gratitude to all the members of the Health Promotion Unit at Maharaj Nakorn Chiang Mai Hospital and the staff of the Department of Community Medicine and the Faculty of Medicine for their valuable contributions to this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: A.K., C.P. (Chanachai Polpitakchai) and K.S.; Methodology: A.K., W.S., C.P. (Chanachai Polpitakchai) and K.S.; Software: W.S.; Validation: A.K., W.S. and J.P.; Formal Analysis: A.K., W.S. and R.S.; Investigation: A.K., R.Y., P.T., C.P. (Chutima Punyaphab), P.S. and C.R.; Resources: P.T. and C.P. (Chutima Punyaphab); Data curation: A.K., C.P. (Chanachai Polpitakchai), J.P. and W.S.; Writing&#x02014;original draft, A.K., C.P. (Chanachai Polpitakchai) and W.S.; Writing&#x02014;review and editing; R.S., P.S., C.R. and K.S.; Supervision: R.S., P.S., C.R. and K.S.; Project administration: A.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Research Ethics Committee, Faculty of Medicine, Chiang Mai University (Ethical approval number: COM-2566-0404, 24 October 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent has been obtained from the patients involved, and they have given approval for this information to be published in this article.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article. Further inquiries can be directed at the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors declare no conflicts of interest. The views and opinions expressed in this article are those of the authors only and do not necessarily represent those of their affiliated institutions.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01381"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Coronavirus Disease (COVID-19) Pandemic</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/europe/emergencies/situations/covid-19" ext-link-type="uri">https://www.who.int/europe/emergencies/situations/covid-19</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-06">(accessed on 6 May 2024)</date-in-citation></element-citation></ref><ref id="B2-vaccines-12-01381"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>COVID-19 Epidemiological Update</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2024</year></element-citation></ref><ref id="B3-vaccines-12-01381"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naughton</surname><given-names>C.C.</given-names></name>
<name><surname>Roman</surname><given-names>F.A.</given-names></name>
<name><surname>Alvarado</surname><given-names>A.G.F.</given-names></name>
<name><surname>Tariqi</surname><given-names>A.Q.</given-names></name>
<name><surname>Deeming</surname><given-names>M.A.</given-names></name>
<name><surname>Kadonsky</surname><given-names>K.F.</given-names></name>
<name><surname>Bibby</surname><given-names>K.</given-names></name>
<name><surname>Bivins</surname><given-names>A.</given-names></name>
<name><surname>Medema</surname><given-names>G.</given-names></name>
<name><surname>Ahmed</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Show us the data: Global COVID-19 wastewater monitoring efforts, equity, and gaps</article-title><source>FEMS Microbes</source><year>2023</year><volume>4</volume><fpage>xtad003</fpage><pub-id pub-id-type="doi">10.1093/femsmc/xtad003</pub-id><pub-id pub-id-type="pmid">37333436</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01381"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Graaf</surname><given-names>M.</given-names></name>
<name><surname>Langeveld</surname><given-names>J.</given-names></name>
<name><surname>Post</surname><given-names>J.</given-names></name>
<name><surname>Carrizosa</surname><given-names>C.</given-names></name>
<name><surname>Franz</surname><given-names>E.</given-names></name>
<name><surname>Izquierdo-Lara</surname><given-names>R.W.</given-names></name>
<name><surname>Elsinga</surname><given-names>G.</given-names></name>
<name><surname>Heijnen</surname><given-names>L.</given-names></name>
<name><surname>Been</surname><given-names>F.</given-names></name>
<name><surname>Van Beek</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Capturing the SARS-CoV-2 infection pyramid within the municipality of Rotterdam using longitudinal sewage surveillance</article-title><source>Sci. Total Environ.</source><year>2023</year><volume>883</volume><fpage>163599</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2023.163599</pub-id><pub-id pub-id-type="pmid">37100150</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01381"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>Dhiyebi</surname><given-names>H.A.</given-names></name>
<name><surname>Varia</surname><given-names>M.</given-names></name>
<name><surname>Atanas</surname><given-names>K.</given-names></name>
<name><surname>Srikanthan</surname><given-names>N.</given-names></name>
<name><surname>Hayat</surname><given-names>S.</given-names></name>
<name><surname>Ikert</surname><given-names>H.</given-names></name>
<name><surname>Fuzzen</surname><given-names>M.</given-names></name>
<name><surname>Sing-Judge</surname><given-names>C.</given-names></name>
<name><surname>Badlani</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Omicron COVID-19 Case Estimates Based on Previous SARS-CoV-2 Wastewater Load, Regional Municipality of Peel, Ontario, Canada</article-title><source>Emerg. Infect. Dis.</source><year>2023</year><volume>29</volume><fpage>1580</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.3201/eid2908.221580</pub-id><pub-id pub-id-type="pmid">37379513</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01381"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Townsend</surname><given-names>J.P.</given-names></name>
<name><surname>Hassler</surname><given-names>H.B.</given-names></name>
<name><surname>Lamb</surname><given-names>A.D.</given-names></name>
<name><surname>Sah</surname><given-names>P.</given-names></name>
<name><surname>Alvarez Nishio</surname><given-names>A.</given-names></name>
<name><surname>Nguyen</surname><given-names>C.</given-names></name>
<name><surname>Tew</surname><given-names>A.D.</given-names></name>
<name><surname>Galvani</surname><given-names>A.P.</given-names></name>
<name><surname>Dornburg</surname><given-names>A.</given-names></name>
</person-group><article-title>Seasonality of endemic COVID-19</article-title><source>mBio</source><year>2023</year><volume>14</volume><elocation-id>e0142623</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.01426-23</pub-id><pub-id pub-id-type="pmid">37937979</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01381"><label>7.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Department of Medical Sciences, Ministry of Public Health</collab>
</person-group><article-title>Thailand Has Discovered the EG.5.1 Lineage, with 5 Cases Reported, but Severity Information Has Not Yet Been Found</article-title><comment>Available online: <ext-link xlink:href="https://www3.dmsc.moph.go.th/post-view/1941" ext-link-type="uri">https://www3.dmsc.moph.go.th/post-view/1941</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-08-22">(accessed on 22 August 2023)</date-in-citation></element-citation></ref><ref id="B8-vaccines-12-01381"><label>8.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Update on COVID-19 in Thailand: 02 May 2024</article-title><comment>Available online: <ext-link xlink:href="https://cdn.who.int/media/docs/default-source/searo/thailand/2024_05_02_tha-sitrep-covid19.pdf?sfvrsn=3491dde6_1" ext-link-type="uri">https://cdn.who.int/media/docs/default-source/searo/thailand/2024_05_02_tha-sitrep-covid19.pdf?sfvrsn=3491dde6_1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-06">(accessed on 6 May 2024)</date-in-citation></element-citation></ref><ref id="B9-vaccines-12-01381"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Surie</surname><given-names>D.</given-names></name>
<name><surname>DeCuir</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Gaglani</surname><given-names>M.</given-names></name>
<name><surname>Ginde</surname><given-names>A.A.</given-names></name>
<name><surname>Douin</surname><given-names>D.J.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
<name><surname>Casey</surname><given-names>J.D.</given-names></name>
<name><surname>Mohr</surname><given-names>N.M.</given-names></name>
<name><surname>Zepeski</surname><given-names>A.</given-names></name>
</person-group><article-title>Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19&#x02013;Associated Hospitalization Among Immunocompetent Adults Aged &#x02265;65 Years&#x02014;IVY Network, 18 States, September 8&#x02013;November 30, 2022</article-title><source>MMWR</source><year>2022</year><volume>71</volume><fpage>1625</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm715152e2</pub-id><pub-id pub-id-type="pmid">36580424</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01381"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azzolini</surname><given-names>E.</given-names></name>
<name><surname>Levi</surname><given-names>R.</given-names></name>
<name><surname>Sarti</surname><given-names>R.</given-names></name>
<name><surname>Pozzi</surname><given-names>C.</given-names></name>
<name><surname>Mollura</surname><given-names>M.</given-names></name>
<name><surname>Mantovani</surname><given-names>A.</given-names></name>
<name><surname>Rescigno</surname><given-names>M.</given-names></name>
</person-group><article-title>Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.11691</pub-id><pub-id pub-id-type="pmid">35796131</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01381"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tartof</surname><given-names>S.Y.</given-names></name>
<name><surname>Slezak</surname><given-names>J.M.</given-names></name>
<name><surname>Fischer</surname><given-names>H.</given-names></name>
<name><surname>Hong</surname><given-names>V.</given-names></name>
<name><surname>Ackerson</surname><given-names>B.K.</given-names></name>
<name><surname>Ranasinghe</surname><given-names>O.N.</given-names></name>
<name><surname>Frankland</surname><given-names>T.B.</given-names></name>
<name><surname>Ogun</surname><given-names>O.A.</given-names></name>
<name><surname>Zamparo</surname><given-names>J.M.</given-names></name>
<name><surname>Gray</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>1407</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02183-8</pub-id><pub-id pub-id-type="pmid">34619098</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01381"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Canetti</surname><given-names>M.</given-names></name>
<name><surname>Barda</surname><given-names>N.</given-names></name>
<name><surname>Gilboa</surname><given-names>M.</given-names></name>
<name><surname>Indenbaum</surname><given-names>V.</given-names></name>
<name><surname>Asraf</surname><given-names>K.</given-names></name>
<name><surname>Gonen</surname><given-names>T.</given-names></name>
<name><surname>Weiss-Ottolenghi</surname><given-names>Y.</given-names></name>
<name><surname>Amit</surname><given-names>S.</given-names></name>
<name><surname>Doolman</surname><given-names>R.</given-names></name>
<name><surname>Mendelson</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>2092</fpage><lpage>2094</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2211283</pub-id><pub-id pub-id-type="pmid">36351266</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01381"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Faraone</surname><given-names>J.</given-names></name>
<name><surname>Evans</surname><given-names>J.P.</given-names></name>
<name><surname>Zou</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.-M.</given-names></name>
<name><surname>Carlin</surname><given-names>C.</given-names></name>
<name><surname>Bednash</surname><given-names>J.S.</given-names></name>
<name><surname>Lozanski</surname><given-names>G.</given-names></name>
<name><surname>Mallampalli</surname><given-names>R.K.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
<etal/>
</person-group><article-title>Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>2526</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2206725</pub-id><pub-id pub-id-type="pmid">35704428</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01381"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abu-Raddad</surname><given-names>L.J.</given-names></name>
<name><surname>Chemaitelly</surname><given-names>H.</given-names></name>
<name><surname>Ayoub</surname><given-names>H.H.</given-names></name>
<name><surname>AlMukdad</surname><given-names>S.</given-names></name>
<name><surname>Yassine</surname><given-names>H.M.</given-names></name>
<name><surname>Al-Khatib</surname><given-names>H.A.</given-names></name>
<name><surname>Smatti</surname><given-names>M.K.</given-names></name>
<name><surname>Tang</surname><given-names>P.</given-names></name>
<name><surname>Hasan</surname><given-names>M.R.</given-names></name>
<name><surname>Coyle</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>1804</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2200797</pub-id><pub-id pub-id-type="pmid">35263534</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01381"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magen</surname><given-names>O.</given-names></name>
<name><surname>Waxman</surname><given-names>J.G.</given-names></name>
<name><surname>Makov-Assif</surname><given-names>M.</given-names></name>
<name><surname>Vered</surname><given-names>R.</given-names></name>
<name><surname>Dicker</surname><given-names>D.</given-names></name>
<name><surname>Hern&#x000e1;n</surname><given-names>M.A.</given-names></name>
<name><surname>Lipsitch</surname><given-names>M.</given-names></name>
<name><surname>Reis</surname><given-names>B.Y.</given-names></name>
<name><surname>Balicer</surname><given-names>R.D.</given-names></name>
<name><surname>Dagan</surname><given-names>N.</given-names></name>
</person-group><article-title>Fourth Dose of BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>1603</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2201688</pub-id><pub-id pub-id-type="pmid">35417631</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01381"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis-Gardner</surname><given-names>M.E.</given-names></name>
<name><surname>Lai</surname><given-names>L.</given-names></name>
<name><surname>Wali</surname><given-names>B.</given-names></name>
<name><surname>Samaha</surname><given-names>H.</given-names></name>
<name><surname>Solis</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>M.</given-names></name>
<name><surname>Porter-Morrison</surname><given-names>A.</given-names></name>
<name><surname>Hentenaar</surname><given-names>I.T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>F.</given-names></name>
<name><surname>Godbole</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>388</volume><fpage>183</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2214293</pub-id><pub-id pub-id-type="pmid">36546661</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01381"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arbel</surname><given-names>R.</given-names></name>
<name><surname>Peretz</surname><given-names>A.</given-names></name>
<name><surname>Sergienko</surname><given-names>R.</given-names></name>
<name><surname>Friger</surname><given-names>M.</given-names></name>
<name><surname>Beckenstein</surname><given-names>T.</given-names></name>
<name><surname>Duskin-Bitan</surname><given-names>H.</given-names></name>
<name><surname>Yaron</surname><given-names>S.</given-names></name>
<name><surname>Hammerman</surname><given-names>A.</given-names></name>
<name><surname>Bilenko</surname><given-names>N.</given-names></name>
<name><surname>Netzer</surname><given-names>D.</given-names></name>
</person-group><article-title>Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: A retrospective cohort study</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>914</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00122-6</pub-id><pub-id pub-id-type="pmid">37062302</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01381"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>D.-Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>D.</given-names></name>
<name><surname>Wheeler</surname><given-names>B.</given-names></name>
<name><surname>Young</surname><given-names>H.</given-names></name>
<name><surname>Sunny</surname><given-names>S.K.</given-names></name>
<name><surname>Moore</surname><given-names>Z.</given-names></name>
</person-group><article-title>Effectiveness of Bivalent Boosters against Severe Omicron Infection</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>764</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2215471</pub-id><pub-id pub-id-type="pmid">36734847</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01381"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Intawong</surname><given-names>K.</given-names></name>
<name><surname>Chariyalertsak</surname><given-names>S.</given-names></name>
<name><surname>Chalom</surname><given-names>K.</given-names></name>
<name><surname>Wonghirundecha</surname><given-names>T.</given-names></name>
<name><surname>Kowatcharakul</surname><given-names>W.</given-names></name>
<name><surname>Thongprachum</surname><given-names>A.</given-names></name>
<name><surname>Chotirosniramit</surname><given-names>N.</given-names></name>
<name><surname>Teacharak</surname><given-names>W.</given-names></name>
<name><surname>Pimpinan</surname><given-names>K.</given-names></name>
<name><surname>Waneesorn</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand: A test-negative, case-control study</article-title><source>Lancet Reg. Health Southeast Asia</source><year>2023</year><volume>10</volume><fpage>100121</fpage><pub-id pub-id-type="doi">10.1016/j.lansea.2022.100121</pub-id><pub-id pub-id-type="pmid">36465090</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01381"><label>20.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Statement on the Antigen Composition of COVID-19 Vaccines</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines" ext-link-type="uri">https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-06">(accessed on 6 May 2024)</date-in-citation></element-citation></ref><ref id="B21-vaccines-12-01381"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelmoneim</surname><given-names>S.A.</given-names></name>
<name><surname>Sallam</surname><given-names>M.</given-names></name>
<name><surname>Hafez</surname><given-names>D.M.</given-names></name>
<name><surname>Elrewany</surname><given-names>E.</given-names></name>
<name><surname>Mousli</surname><given-names>H.M.</given-names></name>
<name><surname>Hammad</surname><given-names>E.M.</given-names></name>
<name><surname>Elkhadry</surname><given-names>S.W.</given-names></name>
<name><surname>Adam</surname><given-names>M.F.</given-names></name>
<name><surname>Ghobashy</surname><given-names>A.A.</given-names></name>
<name><surname>Naguib</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis</article-title><source>Trop. Med. Infect. Dis.</source><year>2022</year><volume>7</volume><elocation-id>298</elocation-id><pub-id pub-id-type="doi">10.3390/tropicalmed7100298</pub-id><pub-id pub-id-type="pmid">36288039</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01381"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitro</surname><given-names>A.</given-names></name>
<name><surname>Sirikul</surname><given-names>W.</given-names></name>
<name><surname>Piankusol</surname><given-names>C.</given-names></name>
<name><surname>Rirermsoonthorn</surname><given-names>P.</given-names></name>
<name><surname>Seesen</surname><given-names>M.</given-names></name>
<name><surname>Wangsan</surname><given-names>K.</given-names></name>
<name><surname>Assavanopakun</surname><given-names>P.</given-names></name>
<name><surname>Surawattanasakul</surname><given-names>V.</given-names></name>
<name><surname>Kosai</surname><given-names>A.</given-names></name>
<name><surname>Sapbamrer</surname><given-names>R.</given-names></name>
</person-group><article-title>Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>7554</fpage><lpage>7561</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.11.031</pub-id><pub-id pub-id-type="pmid">34819224</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01381"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alshahrani</surname><given-names>N.Z.</given-names></name>
<name><surname>Alsabaani</surname><given-names>A.A.</given-names></name>
<name><surname>Ridda</surname><given-names>I.</given-names></name>
<name><surname>Rashid</surname><given-names>H.</given-names></name>
<name><surname>Alzahrani</surname><given-names>F.</given-names></name>
<name><surname>Almutairi</surname><given-names>T.H.</given-names></name>
<name><surname>Alzahrani</surname><given-names>B.A.S.</given-names></name>
<name><surname>Albeshri</surname><given-names>A.S.S.</given-names></name>
</person-group><article-title>Uptake of COVID-19 Booster Dose among Saudi Arabian Population</article-title><source>Medicina</source><year>2022</year><volume>58</volume><elocation-id>972</elocation-id><pub-id pub-id-type="doi">10.3390/medicina58070972</pub-id><pub-id pub-id-type="pmid">35888690</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01381"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>F.</given-names></name>
<name><surname>Cheng</surname><given-names>K.</given-names></name>
<name><surname>Huang</surname><given-names>F.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>H.</given-names></name>
</person-group><article-title>The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><elocation-id>943876</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.943876</pub-id><pub-id pub-id-type="pmid">35979461</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01381"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Della Polla</surname><given-names>G.</given-names></name>
<name><surname>Miraglia Del Giudice</surname><given-names>G.</given-names></name>
<name><surname>Folcarelli</surname><given-names>L.</given-names></name>
<name><surname>Napoli</surname><given-names>A.</given-names></name>
<name><surname>Angelillo</surname><given-names>I.F.</given-names></name>
</person-group><article-title>Willingness to accept a second COVID-19 vaccination booster dose among healthcare workers in Italy</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><elocation-id>1051035</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.1051035</pub-id><pub-id pub-id-type="pmid">36568799</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01381"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>W.</given-names></name>
<name><surname>Alias</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Wong</surname><given-names>L.P.</given-names></name>
</person-group><article-title>Multi-dimensional psychosocial factors influencing the willingness to receive a COVID-19 vaccine booster: A survey among the public in Mainland China</article-title><source>Hum. Vaccin. Immunother.</source><year>2022</year><volume>18</volume><fpage>2126667</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2126667</pub-id><pub-id pub-id-type="pmid">36165498</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01381"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stevens</surname><given-names>C.W.</given-names></name>
<name><surname>Neely</surname><given-names>S.R.</given-names></name>
<name><surname>Scacco</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Breakthrough infections and acceptance of COVID-19 vaccine boosters: A survey analysis</article-title><source>PEC Innov.</source><year>2023</year><volume>2</volume><fpage>100167</fpage><pub-id pub-id-type="doi">10.1016/j.pecinn.2023.100167</pub-id><pub-id pub-id-type="pmid">37214503</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01381"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dudley</surname><given-names>M.Z.</given-names></name>
<name><surname>Schuh</surname><given-names>H.B.</given-names></name>
<name><surname>Forr</surname><given-names>A.</given-names></name>
<name><surname>Shaw</surname><given-names>J.</given-names></name>
<name><surname>Salmon</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Changes in vaccine attitudes and recommendations among US Healthcare Personnel during the COVID-19 pandemic</article-title><source>npj Vaccines</source><year>2024</year><volume>9</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00826-y</pub-id><pub-id pub-id-type="pmid">38418562</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01381"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Link-Gelles</surname><given-names>R.</given-names></name>
<name><surname>Ciesla</surname><given-names>A.A.</given-names></name>
<name><surname>Mak</surname><given-names>J.</given-names></name>
<name><surname>Miller</surname><given-names>J.D.</given-names></name>
<name><surname>Silk</surname><given-names>B.J.</given-names></name>
<name><surname>Lambrou</surname><given-names>A.S.</given-names></name>
<name><surname>Paden</surname><given-names>C.R.</given-names></name>
<name><surname>Shirk</surname><given-names>P.</given-names></name>
<name><surname>Britton</surname><given-names>A.</given-names></name>
<name><surname>Smith</surname><given-names>Z.R.</given-names></name>
<etal/>
</person-group><article-title>Early Estimates of Updated 2023&#x02013;2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults&#x02014;Increasing Community Access to Testing Program, United States, September 2023&#x02013;January 2024</article-title><source>MMWR</source><year>2024</year><volume>73</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7304a2</pub-id><pub-id pub-id-type="pmid">38300853</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01381"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>E.L.-y.</given-names></name>
<name><surname>Qiu</surname><given-names>H.</given-names></name>
<name><surname>Chien</surname><given-names>W.T.</given-names></name>
<name><surname>Wong</surname><given-names>J.C.-l.</given-names></name>
<name><surname>Chalise</surname><given-names>H.N.</given-names></name>
<name><surname>Hoang</surname><given-names>H.T.-x.</given-names></name>
<name><surname>Nguyen</surname><given-names>H.T.</given-names></name>
<name><surname>Chan</surname><given-names>P.K.-s.</given-names></name>
<name><surname>Wong</surname><given-names>M.C.-s.</given-names></name>
<name><surname>Cheung</surname><given-names>A.W.-l.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Vaccine Willingness and Related Factors Among Health Care Workers in 3 Southeast Asian Jurisdictions</article-title><source>JAMA Netw.Open</source><year>2022</year><volume>5</volume><fpage>e2228061</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.28061</pub-id><pub-id pub-id-type="pmid">35994284</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01381"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwok</surname><given-names>K.O.</given-names></name>
<name><surname>Li</surname><given-names>K.K.</given-names></name>
<name><surname>Leung</surname><given-names>C.L.K.</given-names></name>
<name><surname>Tang</surname><given-names>A.</given-names></name>
<name><surname>Chan</surname><given-names>E.Y.Y.</given-names></name>
<name><surname>Tsoi</surname><given-names>M.T.F.</given-names></name>
<name><surname>Wei</surname><given-names>W.I.</given-names></name>
<name><surname>McNeil</surname><given-names>E.B.</given-names></name>
<name><surname>Wong</surname><given-names>S.Y.S.</given-names></name>
</person-group><article-title>The way forward to achieve high COVID-19 vaccination and revaccination coverage in a city amid a period of tranquility</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><elocation-id>935243</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.935243</pub-id><pub-id pub-id-type="pmid">36187671</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01381"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrejko</surname><given-names>K.L.</given-names></name>
<name><surname>Myers</surname><given-names>J.F.</given-names></name>
<name><surname>Fukui</surname><given-names>N.</given-names></name>
<name><surname>Nelson</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>R.</given-names></name>
<name><surname>Openshaw</surname><given-names>J.</given-names></name>
<name><surname>Watt</surname><given-names>J.P.</given-names></name>
<name><surname>Jain</surname><given-names>S.</given-names></name>
<name><surname>Lewnard</surname><given-names>J.A.</given-names></name>
<name><surname>Pry</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>1649</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.01.066</pub-id><pub-id pub-id-type="pmid">36746740</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01381"><label>33.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1" ext-link-type="uri">https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-08">(accessed on 8 October 2024)</date-in-citation></element-citation></ref><ref id="B34-vaccines-12-01381"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cipolletta</surname><given-names>S.</given-names></name>
<name><surname>Andreghetti</surname><given-names>G.R.</given-names></name>
<name><surname>Mioni</surname><given-names>G.</given-names></name>
</person-group><article-title>Risk Perception towards COVID-19: A Systematic Review and Qualitative Synthesis</article-title><source>Int J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>4649</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19084649</pub-id><pub-id pub-id-type="pmid">35457521</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01381"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harapan</surname><given-names>H.</given-names></name>
<name><surname>Anwar</surname><given-names>S.</given-names></name>
<name><surname>Nainu</surname><given-names>F.</given-names></name>
<name><surname>Setiawan</surname><given-names>A.M.</given-names></name>
<name><surname>Yufika</surname><given-names>A.</given-names></name>
<name><surname>Winardi</surname><given-names>W.</given-names></name>
<name><surname>Gan</surname><given-names>A.K.</given-names></name>
<name><surname>Sofyan</surname><given-names>H.</given-names></name>
<name><surname>Mudatsir</surname><given-names>M.</given-names></name>
<name><surname>Oktari</surname><given-names>R.S.</given-names></name>
<etal/>
</person-group><article-title>Perceived Risk of Being Infected with SARS-CoV-2: A Perspective from Indonesia</article-title><source>Disaster. Med. Public Health Prep.</source><year>2022</year><volume>16</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1017/dmp.2020.351</pub-id><pub-id pub-id-type="pmid">32907679</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01381"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sepucha</surname><given-names>K.</given-names></name>
<name><surname>Rudkin</surname><given-names>A.</given-names></name>
<name><surname>Baxter-King</surname><given-names>R.</given-names></name>
<name><surname>Stanton</surname><given-names>A.L.</given-names></name>
<name><surname>Wenger</surname><given-names>N.</given-names></name>
<name><surname>Vavreck</surname><given-names>L.</given-names></name>
<name><surname>Naeim</surname><given-names>A.</given-names></name>
</person-group><article-title>Perceptions of COVID-19 Risk: How Did People Adapt to the Novel Risk?</article-title><source>Med. Decis. Mak.</source><year>2024</year><volume>44</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1177/0272989X231221448</pub-id></element-citation></ref><ref id="B37-vaccines-12-01381"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahrabani</surname><given-names>S.</given-names></name>
<name><surname>Garyn-Tal</surname><given-names>S.</given-names></name>
</person-group><article-title>Emotions, Risk Perception and Preventive Behavior during the COVID-19 Pandemic: The Mediating Role of Media Use</article-title><source>COVID</source><year>2024</year><volume>4</volume><fpage>872</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.3390/covid4070059</pub-id></element-citation></ref><ref id="B38-vaccines-12-01381"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Xiao</surname><given-names>L.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
</person-group><article-title>Spread of misinformation on social media: What contributes to it and how to combat it</article-title><source>Comput. Hum. Behav.</source><year>2023</year><volume>141</volume><fpage>107643</fpage><pub-id pub-id-type="doi">10.1016/j.chb.2022.107643</pub-id></element-citation></ref><ref id="B39-vaccines-12-01381"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ngai</surname><given-names>C.S.B.</given-names></name>
<name><surname>Singh</surname><given-names>R.G.</given-names></name>
<name><surname>Yao</surname><given-names>L.</given-names></name>
</person-group><article-title>Impact of COVID-19 Vaccine Misinformation on Social Media Virality: Content Analysis of Message Themes and Writing Strategies</article-title><source>J. Med. Internet. Res.</source><year>2022</year><volume>24</volume><fpage>e37806</fpage><pub-id pub-id-type="doi">10.2196/37806</pub-id><pub-id pub-id-type="pmid">35731969</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01381"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pal</surname><given-names>S.</given-names></name>
<name><surname>Shekhar</surname><given-names>R.</given-names></name>
<name><surname>Kottewar</surname><given-names>S.</given-names></name>
<name><surname>Upadhyay</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Pathak</surname><given-names>D.</given-names></name>
<name><surname>Kapuria</surname><given-names>D.</given-names></name>
<name><surname>Barrett</surname><given-names>E.</given-names></name>
<name><surname>Sheikh</surname><given-names>A.B.</given-names></name>
</person-group><article-title>COVID-19 Vaccine Hesitancy and Attitude toward Booster Doses among US Healthcare Workers</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1358</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111358</pub-id><pub-id pub-id-type="pmid">34835289</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01381"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
<name><surname>Topol</surname><given-names>E.J.</given-names></name>
</person-group><article-title>COVID-19 vaccine breakthrough infections</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>1561</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1126/science.abl8487</pub-id><pub-id pub-id-type="pmid">34941414</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01381"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>D.-Y.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Paritala</surname><given-names>S.</given-names></name>
<name><surname>Donahue</surname><given-names>M.</given-names></name>
<name><surname>Maloney</surname><given-names>P.</given-names></name>
</person-group><article-title>Durability of XBB.1.5 Vaccines against Omicron Subvariants</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>390</volume><fpage>2124</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2402779</pub-id><pub-id pub-id-type="pmid">38810167</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01381"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>K.Y.K.</given-names></name>
<name><surname>Soh</surname><given-names>A.S.E.</given-names></name>
<name><surname>Ong</surname><given-names>B.W.L.</given-names></name>
<name><surname>Chen</surname><given-names>M.I.</given-names></name>
<name><surname>Griva</surname><given-names>K.</given-names></name>
</person-group><article-title>Determining the Prevalence and Correlates of COVID-19 Booster Vaccine Hesitancy in the Singapore Population Following the Completion of the Primary Vaccination Series</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1088</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10071088</pub-id><pub-id pub-id-type="pmid">35891252</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01381"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galagali</surname><given-names>P.M.</given-names></name>
<name><surname>Kinikar</surname><given-names>A.A.</given-names></name>
<name><surname>Kumar</surname><given-names>V.S.</given-names></name>
</person-group><article-title>Vaccine Hesitancy: Obstacles and Challenges</article-title><source>Curr. Pediatr. Rep.</source><year>2022</year><volume>10</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/s40124-022-00278-9</pub-id><pub-id pub-id-type="pmid">36245801</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01381"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbieri</surname><given-names>V.</given-names></name>
<name><surname>Wiedermann</surname><given-names>C.J.</given-names></name>
<name><surname>Lombardo</surname><given-names>S.</given-names></name>
<name><surname>Piccoliori</surname><given-names>G.</given-names></name>
<name><surname>G&#x000e4;rtner</surname><given-names>T.</given-names></name>
<name><surname>Engl</surname><given-names>A.</given-names></name>
</person-group><article-title>Evolving Altruistic Attitudes towards Vaccination Post COVID-19 Pandemic: A Comparative Analysis across Age Groups</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>454</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12050454</pub-id><pub-id pub-id-type="pmid">38793705</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01381"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steffens</surname><given-names>M.S.</given-names></name>
<name><surname>Bullivant</surname><given-names>B.</given-names></name>
<name><surname>Kaufman</surname><given-names>J.</given-names></name>
<name><surname>King</surname><given-names>C.</given-names></name>
<name><surname>Danchin</surname><given-names>M.</given-names></name>
<name><surname>Hoq</surname><given-names>M.</given-names></name>
<name><surname>Marques</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Testing persuasive messages about booster doses of COVID-19 vaccines on intention to vaccinate in Australian adults: A randomised controlled trial</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0286799</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0286799</pub-id><pub-id pub-id-type="pmid">37267399</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01381"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rzymski</surname><given-names>P.</given-names></name>
<name><surname>Poniedzia&#x00142;ek</surname><given-names>B.</given-names></name>
<name><surname>Fal</surname><given-names>A.</given-names></name>
</person-group><article-title>Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1286</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111286</pub-id><pub-id pub-id-type="pmid">34835217</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01381"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galanis</surname><given-names>P.</given-names></name>
<name><surname>Vraka</surname><given-names>I.</given-names></name>
<name><surname>Katsiroumpa</surname><given-names>A.</given-names></name>
<name><surname>Siskou</surname><given-names>O.</given-names></name>
<name><surname>Konstantakopoulou</surname><given-names>O.</given-names></name>
<name><surname>Katsoulas</surname><given-names>T.</given-names></name>
<name><surname>Mariolis-Sapsakos</surname><given-names>T.</given-names></name>
<name><surname>Kaitelidou</surname><given-names>D.</given-names></name>
</person-group><article-title>First COVID-19 Booster Dose in the General Population: A Systematic Review and Meta-Analysis of Willingness and Its Predictors</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1097</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10071097</pub-id><pub-id pub-id-type="pmid">35891260</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01381"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>N.G.</given-names></name>
<name><surname>Bloom</surname><given-names>D.E.</given-names></name>
<name><surname>Ferranna</surname><given-names>M.</given-names></name>
</person-group><article-title>Factors underlying COVID-19 vaccine and booster hesitancy and refusal, and incentivizing vaccine adoption</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0274529</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0274529</pub-id><pub-id pub-id-type="pmid">36136997</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01381-f001"><label>Figure 1</label><caption><p>Flow diagram of participants&#x02019; enrollment.</p></caption><graphic xlink:href="vaccines-12-01381-g001" position="float"/></fig><table-wrap position="float" id="vaccines-12-01381-t001"><object-id pub-id-type="pii">vaccines-12-01381-t001_Table 1</object-id><label>Table 1</label><caption><p>Sociodemographic and COVID-19-related Information among Thai Healthcare Workers (HCWs) and the Vulnerable Population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sociodemographic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vulnerable Population<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Health <break/>Care Worker<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age in years, mean (SD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.5 (15.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.7 (16.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.2 (13.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">613 (75.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">201 (61.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">412 (85.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body weight &#x02265; 100 kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93 (11.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (15.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 (8.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Education level</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Primary school</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (8.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (19.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Secondary school</td><td align="center" valign="middle" rowspan="1" colspan="1">232 (28.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">105 (32.0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">127 (26.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bachelor&#x02019;s degree</td><td align="center" valign="middle" rowspan="1" colspan="1">404 (49.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">117 (35.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">287 (59.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Master&#x02019;s degree and above</td><td align="center" valign="middle" rowspan="1" colspan="1">106 (13.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (12.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (13.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Chronic medical condition</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cardiovascular</td><td align="center" valign="middle" rowspan="1" colspan="1">308 (38.0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">214 (65.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">94 (19.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">220 (27.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">161 (49.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (12.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="middle" rowspan="1" colspan="1">156 (19.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">137 (41.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (3.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" valign="middle" rowspan="1" colspan="1">158 (19.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">117 (35.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (8.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic Obstructive Pulmonary Disease</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (7.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (7.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (7.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Asthma</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (2.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (4.0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (1.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (3.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (6.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cerebrovascular</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (5.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (8.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (2.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (1.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (2.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.028 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">History of COVID-19 infection</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yourself</td><td align="center" valign="middle" rowspan="1" colspan="1">484 (59.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">153 (46.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">331 (68.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Friends</td><td align="center" valign="middle" rowspan="1" colspan="1">516 (63.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">165 (50.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">351 (72.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Family members</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">519 (64.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124 (37.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">395 (81.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Issues with long COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">163 (20.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46 (14.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117 (24.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of COVID-19 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">774 (95.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">298 (90.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">476 (98.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number of previous COVID-19 vaccination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0 (3.0&#x02013;5.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.0 (2.0&#x02013;4.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0 (3.0&#x02013;5.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Received the Bivalent COVID-19 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">189 (23.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (10.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155 (32.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any side effect from COVID-19 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300 (37.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86 (26.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214 (44.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of flu vaccine last year</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">521 (64.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">157 (47.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">364 (75.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of any vaccine refusal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">241 (29.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58 (17.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">183 (37.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Will receive the latest COVID-19 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">356 (44.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">147 (44.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209 (43.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.640</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic toggle="yes">p</italic>-value &#x0003c; 0.05, ** <italic toggle="yes">p</italic>-value &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01381-t002"><object-id pub-id-type="pii">vaccines-12-01381-t002_Table 2</object-id><label>Table 2</label><caption><p>Attitudes toward COVID-19 Disease and COVID-19 Vaccination Among Thai Healthcare Workers (HCWs) and the Vulnerable Group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Perceived Risk</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vulnerable Population<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Healthcare Workers<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">The risk level for contracting COVID-19 in the future</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">274 (83.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">288 (59.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 (15.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">195 (40.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">Severity level of COVID-19</td><td align="center" valign="middle" rowspan="1" colspan="1">Low severity</td><td align="center" valign="middle" rowspan="1" colspan="1">209 (63.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">336 (69.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High severity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116 (35.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">147 (30.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">COVID-19 impacts your daily life</td><td align="center" valign="middle" rowspan="1" colspan="1">Low impact</td><td align="center" valign="middle" rowspan="1" colspan="1">198 (60.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">304 (62.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.380</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High impact</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">129 (39.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">179 (37.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">COVID-19 impact your work life</td><td align="center" valign="middle" rowspan="1" colspan="1">Low impact</td><td align="center" valign="middle" rowspan="1" colspan="1">196 (59.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">249 (51.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.030</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High impact</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131 (39.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">234 (48.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">Concerns about receiving a booster vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Low risk</td><td align="center" valign="middle" rowspan="1" colspan="1">217 (66.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">327 (67.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High risk</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110 (33.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156 (32.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">Concerned about the side effects of booster vaccines</td><td align="center" valign="middle" rowspan="1" colspan="1">Low concern</td><td align="center" valign="middle" rowspan="1" colspan="1">192 (58.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">303 (62.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.250</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High concern</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135 (41.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">180 (37.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">Believe booster vaccines are safe</td><td align="center" valign="middle" rowspan="1" colspan="1">Low beliefs</td><td align="center" valign="middle" rowspan="1" colspan="1">231 (70.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">383 (79.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High beliefs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96 (29.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 (20.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">Believe booster vaccines will prevent infection with new strains of COVID-19</td><td align="center" valign="middle" rowspan="1" colspan="1">Low beliefs</td><td align="center" valign="middle" rowspan="1" colspan="1">249 (75.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">393 (81.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.095</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High beliefs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (23.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 (18.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="top" style="border-bottom:solid thin" colspan="1">believe booster vaccines will prevent severe infection from new variants of COVID-19</td><td align="center" valign="middle" rowspan="1" colspan="1">Low beliefs</td><td align="center" valign="middle" rowspan="1" colspan="1">219 (66.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">339 (70.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.300</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High beliefs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108 (32.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">144 (9.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic toggle="yes">p</italic>-value &#x0003c; 0.05, ** <italic toggle="yes">p</italic>-value &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01381-t003"><object-id pub-id-type="pii">vaccines-12-01381-t003_Table 3</object-id><label>Table 3</label><caption><p>Factors influencing COVID-19 Booster willingness among Thai Healthcare Workers (HCWs) and the Vulnerable Population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vulnerable Population<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Healthcare Workers<break/><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">The biggest influence of getting the vaccine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Yourself</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">687 (84.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">256 (78.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">431 (89.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Friend and Family member</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">283 (34.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160 (48.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123 (25.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Vaccine expert</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">168 (20.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (15.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118 (24.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Government</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95 (11.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 (12.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (11.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.710</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Community</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (4.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (8.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (1.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any concerns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">565 (69.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">239 (73.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">326 (67.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.097</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Side effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">483 (59.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">194 (59.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">289 (60.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.860</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Efficacy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">310 (38.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119 (36.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">191 (39.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.350</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">241 (29.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 (26.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">154 (32.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Research on vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">510 (63.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">198 (60.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">312 (64.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.230</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Safety</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">239 (29.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (23.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161 (33.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003 *</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Source of information</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Friend</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">444 (54.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">175 (53.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">269 (55.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.520</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Internet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237 (29.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127 (38.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110 (22.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Healthcare Workers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">197 (24.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111 (33.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86 (17.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Offline </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160 (19.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68 (20.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92 (19.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.550</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic toggle="yes">p</italic>-value &#x0003c; 0.05, ** <italic toggle="yes">p</italic>-value &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01381-t004"><object-id pub-id-type="pii">vaccines-12-01381-t004_Table 4</object-id><label>Table 4</label><caption><p>Factors associated with COVID-19 vaccine willingness in the post-pandemic era among HCWs and this vulnerable population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">COVID-19 Vaccine Willingness</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">aORs</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">95% CI</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UCI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LCI</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Sociodemographic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthcare workers (reference: high-risk group)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.040 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body weight &#x0003e; 100 kg.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002 *</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Chronic medical conditions </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory diseases (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.161</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiovascular diseases (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.465</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic kidney disease (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.680</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cerebrovascular (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.434</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.925</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes mellitus (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.622</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">History of COVID-19 infection </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yourself (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.368</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Friends (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.548</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Family member (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.309</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Issues with Long COVID-19 (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.056</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number of COVID-19 vaccination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Have you received the (Bivalent) vaccine (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.750</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Side effects from COVID-19 vaccine (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.088</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of flu vaccine last year (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of any vaccine refusal (reference: no)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005 *</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Attitude toward COVID-19 disease and COVID-19 vaccination (reference: low perceived)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk levels for contracting COVID-19 in the future</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.092</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severity levels of COVID-19?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.464</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 impacting your daily life</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.040 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 impacting your work life</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.042 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concerns about receiving a booster vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concerned about the side effects of booster vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.201</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Believe booster vaccines are safe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Believe booster vaccines will prevent infection with new strains of COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.715</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Believe booster vaccines will prevent severe infection from new variants of COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001 **</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviation: aOR, adjusted Odds Ratio; 95% CI, 95% confidence interval. aOR was obtained by a multivariable logistic regression model adjusted for age, gender, education levels, and marital status. * <italic toggle="yes">p</italic>-value &#x0003c; 0.05, ** <italic toggle="yes">p</italic>-value &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap></floats-group></article>